title: Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections.
abstract: Tigecycline (TG) has been shown to be active in vitro against Acinetobacter baumannii, although data on the clinical efficacy of TG alone or in combination for the treatment of infections due to multidrug-resistant A. baumannii (MDRAB) remain limited. The purpose of this study was to investigate the clinical outcomes of patients with healthcare-associated infections (HAIs) caused by MDRAB who were treated with imipenem/cilastatin and sulbactam, and TG alone or in combination with other antibiotics. A total of 386 patients with HAIs caused by MDRAB were retrospectively analyzed and grouped into TG and non-TG groups, depending on whether they received TG treatment. Of the 266 patients in the TG group, 108 were treated with TG alone and 158 were treated with TG in combination with ceftazidime, ceftriaxone, piperacillin/tazobactam, or a carbapenem. All 120 patients in the non-TG group were treated with imipenem/cilastatin and sulbactam. The primary outcome measure was 30-day mortality after TG treatment and the secondary outcome was clinical outcome. There were no significant differences in survival rates between the two groups. However, the rate of unfavorable outcome was significantly lower (p < 0.05) among patients in the TG group than among patients in the non-TG group. The most significant predictor of unfavorable outcome was sepsis, whereas TG treatment and microbial eradication were the most significant predictors of favorable outcomes. Our study represents the largest study of patients with MDRAB infection treated with TG and expands our understanding of the role of TG therapy alone or in combination with other agents for the treatment of HAI caused by MDRAB.
authors.affiliation: Institute of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
authors.forename: Y-T
authors.initials: YT
authors.lastname: Lee
authors.forename: S-M
authors.initials: SM
authors.lastname: Tsao
authors.forename: P-R
authors.initials: PR
authors.lastname: Hsueh
mesh_terms: D000151:Acinetobacter Infections / Q000188:drug therapy*; D040981:Acinetobacter baumannii / Q000187:drug effects*; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002442:Ceftazidime / Q000627:therapeutic use; D002443:Ceftriaxone / Q000627:therapeutic use; D015377:Cilastatin / Q000627:therapeutic use; D003428:Cross Infection / Q000188:drug therapy*; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D008297:Male; D008911:Minocycline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010878:Piperacillin / Q000627:therapeutic use; D013407:Sulbactam / Q000627:therapeutic use; D000078304:Tigecycline; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D015377:Cilastatin; D000078304:Tigecycline; D015378:Imipenem; D002443:Ceftriaxone; D002442:Ceftazidime; D008911:Minocycline; D013407:Sulbactam; D010878:Piperacillin
references.citation: J Clin Microbiol. 2007 May;45(5):1551-5
references.pmid: 17314222
references.citation: Antimicrob Agents Chemother. 2012 Mar;56(3):1452-7
references.pmid: 22203598
references.citation: Lancet. 1974 Jul 13;2(7872):81-4
references.pmid: 4136544
references.citation: BMC Infect Dis. 2005 Oct 19;5:88
references.pmid: 16236177
references.citation: Diagn Microbiol Infect Dis. 2005 Jul;52(3):173-9
references.pmid: 16105561
references.citation: Infection. 2011 Dec;39(6):515-8
references.pmid: 21789524
references.citation: J Chemother. 2008 Feb;20(1):69-76
references.pmid: 18343747
references.citation: J Antimicrob Chemother. 2011 Jul;66(7):1625-30
references.pmid: 21586594
references.citation: Emerg Infect Dis. 2007 Jan;13(1):97-103
references.pmid: 17370521
references.citation: J Antimicrob Chemother. 2011 Sep;66(9):1963-71
references.pmid: 21685488
references.citation: J Antimicrob Chemother. 2008 Jul;62(1):45-55
references.pmid: 18436554
references.citation: Antimicrob Agents Chemother. 2004 Dec;48(12):4919-21
references.pmid: 15561882
references.citation: Microb Drug Resist. 2008 Sep;14(3):233-7
references.pmid: 18707240
references.citation: Clin Infect Dis. 2012 Jun;54(12):1710-3
references.pmid: 22467671
references.citation: BMC Infect Dis. 2010 Sep 29;10:287
references.pmid: 20920273
references.citation: Antimicrob Agents Chemother. 2004 Nov;48(11):4479-81
references.pmid: 15504889
references.citation: J Antimicrob Chemother. 2010 Nov;65 Suppl 3:iii35-44
references.pmid: 20876627
references.citation: J Antimicrob Chemother. 2009 Apr;63(4):775-80
references.pmid: 19158109
references.citation: Crit Care Med. 2009 Mar;37(3):840-51; quiz 859
references.pmid: 19237886
references.citation: Crit Care Med. 2007 Aug;35(8):1888-95
references.pmid: 17581492
references.citation: Clin Infect Dis. 2006 Mar 1;42(5):692-9
references.pmid: 16447117
references.citation: Clin Infect Dis. 2010 Jul 1;51(1):79-84
references.pmid: 20504234
references.citation: Clin Microbiol Rev. 2008 Jul;21(3):538-82
references.pmid: 18625687
references.citation: J Glob Infect Dis. 2010 Sep;2(3):291-304
references.pmid: 20927292
references.citation: N Engl J Med. 2010 May 13;362(19):1804-13
references.pmid: 20463340
references.citation: J Postgrad Med. 2009 Jan-Mar;55(1):65-8
references.pmid: 19242083
references.citation: Am J Infect Control. 1988 Jun;16(3):128-40
references.pmid: 2841893
references.citation: Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S341-53
references.pmid: 16080072
references.citation: J Antimicrob Chemother. 2008 Nov;62(5):895-904
references.pmid: 18676620
references.citation: Crit Care Med. 2005 Oct;33(10):2373-82
references.pmid: 16215395
references.citation: J Antimicrob Chemother. 2001 Apr;47(4):479-82
references.pmid: 11266426
references.citation: Antimicrob Agents Chemother. 2007 Oct;51(10):3471-84
references.pmid: 17646423
references.citation: J Antimicrob Chemother. 2007 Jan;59(1):128-31
references.pmid: 17082201
references.citation: Diagn Microbiol Infect Dis. 2010 Oct;68(2):140-51
references.pmid: 20846586
references.citation: J Antimicrob Chemother. 2008 Sep;62 Suppl 1:i29-40
references.pmid: 18684704
references.citation: Ann Pharmacother. 2008 Sep;42(9):1188-94
references.pmid: 18614749
references.citation: Crit Care Med. 1981 Aug;9(8):591-7
references.pmid: 7261642
references.citation: Clin Infect Dis. 2002 Jun 1;34(11):1425-30
references.pmid: 12015687
references.citation: Am J Infect Control. 2008 Jun;36(5):309-32
references.pmid: 18538699
references.citation: Indian J Med Microbiol. 2012 Jan-Mar;30(1):69-75
references.pmid: 22361764
references.citation: Yonsei Med J. 2012 Sep;53(5):974-84
references.pmid: 22869481
references.citation: Infect Control Hosp Epidemiol. 2007 Jun;28(6):713-9
references.pmid: 17520546
references.citation: Ann Intensive Care. 2011 Nov 23;1:47
references.pmid: 22112929
references.citation: Intensive Care Med. 1996 Jul;22(7):707-10
references.pmid: 8844239
references.citation: Clin Infect Dis. 2012 Jun;54(12):1699-709
references.pmid: 22467668
references.citation: J Antimicrob Chemother. 2004 Feb;53(2):393-5
references.pmid: 14729739
references.citation: Clin Infect Dis. 2008 Apr 15;46(8):1254-63
references.pmid: 18444865
references.citation: Microbiol Mol Biol Rev. 2001 Jun;65(2):232-60 ; second page, table of contents
references.pmid: 11381101